Table 2 Patient characteristics and... | American Society of Hematology

Table 2

Patient characteristics and treatment outcomes in the UKCLL05 pilot study of subcutaneous alemtuzumab

Patient no.	Sex	Age, y	WBC, × 10⁹/L	Alemtuzumab, wk	Response after subcutaneous alemtuzumab	Intravenous alemtuzumab given	Response after intravenous alemtuzumab	Pentostatin added	Response after pentostatin	Stem cell transplant	Disease progression	PFS from start alemtuzumab, mo	Vital status	OS from start alemtuzumab, mo
1	Female	79	217	7	CR	No	—	No	—	No	Yes	34	Alive	53
2	Male	66	118	11	CR	No	—	No	—	Autograft	Yes	21*	Died	40
3	Female	61	56	14	CR	No	—	No	—	Allograft	No	46	Alive	46
4	Male	78	115	9	NR	Yes	CR	No	—	No	Yes	13*	Died	26
5	Female	41	206	15	NR	Yes	NR	Yes	CR	Allograft	No	51	Alive	51
6	Male	60	183	12	NR	Yes	NR	Yes	CR	Allograft	Yes	11	Died	18
7	Male	50	203	13	NR	Yes	NR	Yes	NR†	Allograft	Yes	0	Died	18
8	Male	36	73	4	NR	Yes	NR	Yes	NR	No	Yes	0	Died	1
9	Male	76	205	8	NR	No	—	Yes	NR	No	Yes	0	Died	2

Patient no.	Sex	Age, y	WBC, × 10⁹/L	Alemtuzumab, wk	Response after subcutaneous alemtuzumab	Intravenous alemtuzumab given	Response after intravenous alemtuzumab	Pentostatin added	Response after pentostatin	Stem cell transplant	Disease progression	PFS from start alemtuzumab, mo	Vital status	OS from start alemtuzumab, mo
1	Female	79	217	7	CR	No	—	No	—	No	Yes	34	Alive	53
2	Male	66	118	11	CR	No	—	No	—	Autograft	Yes	21*	Died	40
3	Female	61	56	14	CR	No	—	No	—	Allograft	No	46	Alive	46
4	Male	78	115	9	NR	Yes	CR	No	—	No	Yes	13*	Died	26
5	Female	41	206	15	NR	Yes	NR	Yes	CR	Allograft	No	51	Alive	51
6	Male	60	183	12	NR	Yes	NR	Yes	CR	Allograft	Yes	11	Died	18
7	Male	50	203	13	NR	Yes	NR	Yes	NR†	Allograft	Yes	0	Died	18
8	Male	36	73	4	NR	Yes	NR	Yes	NR	No	Yes	0	Died	1
9	Male	76	205	8	NR	No	—	Yes	NR	No	Yes	0	Died	2

WBC indicates white blood cell; —, not applicable; and NR, nonresponse.

Re-treated with alemtuzumab (intravenously) achieving second response.

Achieved good PR after DexaBEAM before allograft.